<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>40(1)</volume><submitter>Jung D</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Recently, allogeneic natural killer (NK) cells have gained considerable attention as promising immunotherapeutic tools due to their unique biological functions and characteristics. Although many NK expansion strategies have been reported previously, a deeper understanding of cryopreserved allogeneic NK cells is needed for specific therapeutic approaches.&lt;h4>Methods&lt;/h4>We isolated CD3&lt;sup>-&lt;/sup>CD56&lt;sup>+&lt;/sup> primary natural killer (pNK) cells from healthy donors and expanded them ex vivo using a GMP-compliant method without any feeder to generate large volumes of therapeutic pNK cells and cryopreserved stocks. After validation for high purity and activating phenotypes, we performed RNA sequencing of the expanded and cryopreserved pNK cells. The pNK cells were used ag</pubmed_abstract><journal>Journal of experimental &amp; clinical cancer research : CR</journal><pagination>333</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8539797</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions.</pubmed_title><pmcid>PMC8539797</pmcid><pubmed_authors>Jung D</pubmed_authors><pubmed_authors>An HJ</pubmed_authors><pubmed_authors>Baek YS</pubmed_authors><pubmed_authors>Jung J</pubmed_authors><pubmed_authors>Hwang S</pubmed_authors><pubmed_authors>Moon YW</pubmed_authors><pubmed_authors>Lee IJ</pubmed_authors><pubmed_authors>Jang H</pubmed_authors><pubmed_authors>Kim KY</pubmed_authors><pubmed_authors>Park KS</pubmed_authors><pubmed_authors>Choi YS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions.</name><description>&lt;h4>Background&lt;/h4>Recently, allogeneic natural killer (NK) cells have gained considerable attention as promising immunotherapeutic tools due to their unique biological functions and characteristics. Although many NK expansion strategies have been reported previously, a deeper understanding of cryopreserved allogeneic NK cells is needed for specific therapeutic approaches.&lt;h4>Methods&lt;/h4>We isolated CD3&lt;sup>-&lt;/sup>CD56&lt;sup>+&lt;/sup> primary natural killer (pNK) cells from healthy donors and expanded them ex vivo using a GMP-compliant method without any feeder to generate large volumes of therapeutic pNK cells and cryopreserved stocks. After validation for high purity and activating phenotypes, we performed RNA sequencing of the expanded and cryopreserved pNK cells. The pNK cells were used ag</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Oct</publication><modification>2026-05-08T16:11:12.265Z</modification><creation>2025-04-04T19:50:32.629Z</creation></dates><accession>S-EPMC8539797</accession><cross_references><pubmed>34686187</pubmed><doi>10.1186/s13046-021-02089-0</doi></cross_references></HashMap>